Marinus Pharmaceuticals Inc (MRNS)

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile

Marinus Pharmaceuticals Inc

484-801-4670

5 RADNOR CORPORATE CENTER SUITE 500, RADNOR, PA

Nächster Verdiensttermin

Neueste SEC-Einreichungen

MRNS's Discussions on Twitter

Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-01-20	Eingeleitet	RBC Capital Mkts	Outperform
2020-09-30	Eingeleitet	Truist	Buy
2020-07-01	Eingeleitet	Cowen	Outperform
2020-07-01	Bestätigt	H.C. Wainwright	Buy
2020-04-09	Eingeleitet	Craig Hallum	Buy
2019-12-20	Eingeleitet	Oppenheimer	Outperform
2019-03-05	Fortgesetzt	Jefferies	Buy
2019-02-27	Herabstufung	Mizuho	Buy → Neutral
2019-02-06	Eingeleitet	Leerink Partners	Outperform
2018-07-02	Eingeleitet	Cantor Fitzgerald	Overweight
2018-03-20	Eingeleitet	Mizuho	Buy
2018-02-15	Eingeleitet	H.C. Wainwright	Buy
2017-12-14	Eingeleitet	Laidlaw	Buy
2016-08-10	Bestätigt	Jefferies	Buy
2016-06-14	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2016-03-08	Bestätigt	Stifel	Buy
2015-12-17	Eingeleitet	RBC Capital Mkts	Outperform
2015-11-17	Eingeleitet	Jefferies	Buy
2015-10-30	Bestätigt	Oppenheimer	Outperform
2015-08-05	Bestätigt	Oppenheimer	Outperform

Alle ansehen

Marinus Pharmaceuticals Inc Aktie (MRNS) Neueste Nachrichten

Finanzdaten der Marinus Pharmaceuticals Inc-Aktie (MRNS)

Marinus Pharmaceuticals Inc-Aktie (MRNS) Insiderhandel

Insiderhandel	Beziehung	Datum	Transaktion	Kosten	#Aktien	Wert ($)	#Aktien Gesamt
Shafer Christina	CHIEF COMMERCIAL OFFICER	Aug 05 '24	Sale	1.14	3,820	4,355	67,406
MANNING MARTHA E	SVP, GEN. COUNSEL & CORP. SEC.	Aug 05 '24	Sale	1.13	3,621	4,092	60,263
Hulihan Joseph	CHIEF MEDICAL OFFICER	Aug 05 '24	Sale	1.13	4,828	5,456	72,725
Braunstein Scott	CHAIRMAN AND CEO	Aug 05 '24	Sale	1.13	12,145	13,724	298,667
Braunstein Scott	CHAIRMAN AND CEO	Mar 27 '24	Option Exercise	4.28	50,000	214,000	273,512
Shafer Christina	CHIEF COMMERCIAL OFFICER	Feb 20 '24	Sale	9.56	2,153	20,583	60,308
MANNING MARTHA E	SVP, GEN. COUNSEL & CORP. SEC.	Feb 20 '24	Sale	9.57	1,894	18,126	52,966
Hulihan Joseph	CHIEF MEDICAL OFFICER	Feb 16 '24	Sale	9.98	2,814	28,084	66,635
Pfanstiel Steven	CFO AND COO	Feb 16 '24	Sale	9.97	3,092	30,827	71,697
Braunstein Scott	CHAIRMAN AND CEO	Feb 16 '24	Sale	9.94	11,850	117,789	223,512

Marinus Pharmaceuticals Inc (MRNS)

Marinus Pharmaceuticals Inc Stock (MRNS) Company Profile

Marinus Pharmaceuticals Inc Stock (MRNS) Upgrades & Downgrades

Marinus Pharmaceuticals Inc Aktie (MRNS) Neueste Nachrichten

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 - BioSpace

Marinus Pharmaceuticals Announces Agenda and Speakers for Investor & Analyst Day on September 20, 2024 - StockTitan

Marinus Pharmaceuticals to Present at the 2024 Cantor Global Healthcare Conference - StockTitan

Marinus Pharmaceuticals (NASDAQ:MRNS) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat

Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Upgraded by StockNews.com - MarketBeat

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Receives $12.75 Average PT from Analysts - MarketBeat

Marinus Pharmaceuticals Inc (MRNS) may enjoy gains as insiders got busy in the recent days - Knox Daily

Marinus Pharmaceuticals Hosts Investor and Analyst Day - MyChesCo

Marinus Pharmaceuticals (NASDAQ:MRNS) Downgraded by StockNews.com to "Sell" - MarketBeat

Marinus Pharmaceuticals Reports Robust Q2 2024 Financial Results and Business Progress - MyChesCo

Cantor Fitzgerald Weighs in on Marinus Pharmaceuticals, Inc.'s FY2024 Earnings (NASDAQ:MRNS) - MarketBeat

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 - StockTitan

Marinus Pharmaceuticals to Host Investor and Analyst Day on Friday, September 20, 2024 - Business Wire

LADENBURG THALM/SH SH Lowers Marinus Pharmaceuticals (NASDAQ:MRNS) to Neutral - Defense World

Marinus Pharmaceuticals (LTS:0JYL) Asset Turnover : 0.07 (As of Jun. 2024) - GuruFocus.com

Q3 2024 EPS Estimates for Marinus Pharmaceuticals, Inc. Reduced by HC Wainwright (NASDAQ:MRNS) - MarketBeat

Leerink Partnrs Brokers Cut Earnings Estimates for Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) - Defense World

Marinus Pharmaceuticals (NASDAQ:MRNS) Stock Rating Reaffirmed by HC Wainwright - Defense World

Marinus Pharmaceuticals, Inc. Expected to Post Q3 2024 Earnings of ($0.47) Per Share (NASDAQ:MRNS) - Defense World

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Simply Wall St

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance

Thinking about buying stock in Archer Aviation, Marinus Pharmace - GuruFocus.com

Marinus Pharmaceuticals, Inc. Forecasted to Earn FY2028 Earnings of $2.72 Per Share (NASDAQ:MRNS) - MarketBeat

Marinus Pharmaceuticals, Inc. Forecasted to Earn FY2028 Earnings of $2.72 Per Share (NASDAQ:MRNS) - Defense World

Marinus Pharmaceuticals (NASDAQ:MRNS) Upgraded by StockNews.com to Hold - Defense World

Marinus Pharmaceuticals (NASDAQ:MRNS) Given "Buy" Rating at HC Wainwright - MarketBeat

Marinus Pharma stock hits 52-week low at $1.09 amid downturn - Investing.com

Global Maternal Mental Health Market to Exhibit Growth at Tremendous CAGR of ~15% by 2030 | DelveInsight - GlobeNewswire Inc.

Marinus Pharma stock hits 52-week low at $1.09 amid downturn - Investing.com Australia

Marinus Pharma stock hits 52-week low at $1.09 amid downturn - Investing.com Canada

Marinus Pharma stock hits 52-week low at $1.09 amid downturn - Investing.com India

Marinus Pharmaceuticals Inc (MRNS) Q2 2024 Earnings Call Transcr - GuruFocus.com

Company News for Aug 14, 2024 - MSN

Marinus Pharma stock hits 52-week low at $1.09 amid downturn - Investing.com UK

Company News for Aug 14, 2024 - Yahoo Finance

Marinus Pharmaceuticals (NASDAQ:MRNS) Cut to Neutral at LADENBURG THALM/SH SH - MarketBeat

Marinus Pharmaceuticals: Q2 Earnings Snapshot - Darien Times

MRNS Investors Have Opportunity to Lead Marinus Pharmaceuticals, Inc. Securities Fraud Lawsuit - Longview News-Journal

Marinus Pharmaceuticals maintains Buy rating with $10 target By Investing.com - Investing.com Canada

Earnings call: Marinus Pharmaceuticals reports steady ZTALMY growth By Investing.com - Investing.com Australia

Earnings call: Marinus Pharmaceuticals reports steady ZTALMY growth By Investing.com - Investing.com Canada

Earnings call: Marinus Pharmaceuticals reports steady ZTALMY growth - Investing.com India

Earnings call: Marinus Pharmaceuticals reports steady ZTALMY growth - Investing.com

Earnings call: Marinus Pharmaceuticals reports steady ZTALMY growth By Investing.com - Investing.com UK

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results - citybiz

Marinus Pharmaceuticals: Q2 Earnings Snapshot - San Francisco Chronicle

Marinus Pharmaceuticals: Q2 Earnings Snapshot - The Washington Post

Marinus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results - Lelezard

Marinus Pharmaceuticals (MRNS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Canada Finance

Marinus Pharma falls after missing Q2 revenue estimates - XM

Marinus Pharmaceuticals: Q2 Earnings Snapshot - CTPost

Finanzdaten der Marinus Pharmaceuticals Inc-Aktie (MRNS)

Umsatz

Nettogewinn

Free Cashflow

ENV

Marinus Pharmaceuticals Inc-Aktie (MRNS) Insiderhandel

Ähnlich wie MRNS